Loading organizations...
Based in Manchester, England, Cytotrait is an agricultural biotechnology company that develops novel crop traits by reprogramming chloroplast and mitochondrial genomes. Operating as a 2023 spinout from the University of Manchester founded by Dr. Junwei Ji, the organization utilizes its proprietary Mutant Organelle Selection System to achieve rapid homoplasmy and elevated trait expression in major agricultural commodities, including wheat, maize, potato, and canola. In March 2026, the enterprise secured £3 million in seed funding led by Northern Gritstone, with participation from UKI2S and the Northern Universities Ventures Fund managed by Parkwalk, to expand its global crop programs. This recent financing builds upon a previous £498,000 grant from the Advanced Research and Invention Agency for wheat hybrid seed production. To support this commercial expansion, the firm appointed Dr. Timothy Brears and Cassandra Clare Doherty as directors in February 2026.
Cytotrait has raised $4.0M across 1 funding round.
Cytotrait has raised $4.0M in total across 1 funding round.
Cytotrait has raised $4.0M in total across 1 funding round.
Cytotrait's investors include Northern Gritstone, Duncan Johnson, Northern Universities Ventures Fund, Hassan Mahmudul.
Cytotrait has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Seed in March 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 26, 2026 | $4M Seed | Northern Gritstone, Duncan Johnson | Northern Universities Ventures Fund, Hassan Mahmudul | Announced |
